Compare TER & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TER | ZTS |
|---|---|---|
| Founded | 1960 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.1B | 48.7B |
| IPO Year | 1994 | 2012 |
| Metric | TER | ZTS |
|---|---|---|
| Price | $367.43 | $117.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 11 |
| Target Price | ★ $281.92 | $156.20 |
| AVG Volume (30 Days) | 2.7M | ★ 3.0M |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | 0.14% | ★ 1.77% |
| EPS Growth | 4.52 | ★ 10.05 |
| EPS | 3.47 | ★ 6.02 |
| Revenue | $3,190,024,000.00 | ★ $9,467,000,000.00 |
| Revenue This Year | $32.19 | $5.68 |
| Revenue Next Year | $18.24 | $4.86 |
| P/E Ratio | $104.71 | ★ $19.92 |
| Revenue Growth | ★ 13.13 | 2.28 |
| 52 Week Low | $68.24 | $113.30 |
| 52 Week High | $369.64 | $172.23 |
| Indicator | TER | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 68.41 | 46.35 |
| Support Level | $275.22 | $115.35 |
| Resistance Level | N/A | $129.28 |
| Average True Range (ATR) | 16.55 | 2.82 |
| MACD | 6.91 | 0.59 |
| Stochastic Oscillator | 94.43 | 57.99 |
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems, and wireless testing for devices. The firm entered the industrial automation market in 2015 and sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies, directly and indirectly, through its products, but its most significant exposure is to semiconductor testing. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its USA business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.